Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumours experienced prolonged survival after following treatment with ipilimumab in a Phase II trial at The University of Texas MD Anderson Cancer Center.
The results, published today in Science Translational Medicine, suggest that certain patients with mCRPC may benefit from immune checkpoint inhibitors and provide biomarkers for identifying this subgroup.
"Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumour neoantigens despite a low tumour mutational burden in prostate cancer," said lead author Sumit Subudhi, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology.
"We found specific markers among a subset of patients with the greatest benefit, such as T-cell density and interferon-γ signalling, that may help improve our ability to select patients for treatment with checkpoint blockade."
Cancers with the strongest responses to immune checkpoint inhibitors, such as melanoma or lung cancer, tend to have high levels of underlying gene mutations, which leads to production of mutation proteins, or neoantigens, that can be recognised as abnormal by the immune system.
Prostate cancers have relatively low mutation levels and fewer neoantigens present.
However, small groups of mCRPC patients within larger Phase III trials have seen favourable outcomes to checkpoint inhibitors, explained Subudhi, which drove the researchers to ask whether effective immune responses could be stimulated by checkpoint blockade in tumours with low mutation levels.
To investigate this question, the research team launched the Phase II trial in collaboration with MD Anderson's immunotherapy platform, which is co-led by corresponding author Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology.
The platform is part of the institution's Moon Shots Program, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patient's lives.
The trial enrolled 30 MD Anderson patients with mCRPC between January 2015 and May 2018. Of those, 29 received at least one dose of ipilimumab and were able to be included in the final analysis. Median follow-up after the first treatment was 45.5 months.
Across all patients, median progression-free survival (PFS) according to radiographic imaging was 3 months, and median overall survival (OS) was 24.3 months.
Eight patients (28%) experienced grade 3 toxicities, the most common of which were dermatitis and diarrhoea, and none experienced grade 4 or 5 toxicities.
The researchers noted a "favourable" cohort of nine patients with PFS greater than six months and OS greater than one year, and an "unfavourable" cohort of ten patients with PFS less than six months and OS less than one year.
At the time of analysis, six (67%) patients from the "favourable" cohort were alive, with survival ranging between 33 and 54 months.
By comparing pretreatment samples from these two cohorts, the researchers identified markers associated with improved responses to checkpoint blockade. Those in the "favourable" cohort had a higher density of cytotoxic and memory T cells in the tumour as well as increased expression of interferon (IFN)-γ signalling.
Further, the researchers showed that T cells isolated from patients in the "favourable" cohort were capable of recognising and responding to the neoantigens present in their tumour, whereas T cells from patients in the "unfavourable" group did not appear to have the same responses.
"We were encouraged to see that prostate cancers with a low mutational burden do in fact express neoantigens that elicit T-cell responses that lead to favourable clinical outcomes," said Sharma.
"Our findings indicate that anti-CTLA-4 immune checkpoint therapy warrants additional studies in order to develop treatment strategies that may improve survival of patients with metastatic prostate cancer."
Moving forward, the authors plan to investigate this question in larger, multi-institutional studies to validate the findings of the current trial.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.